ACAD
41.69
+0.02
+0.05%
AEMD
6.9
-0.1
-1.43%
APRI
1.85
+0.17
+10.12%
ARNA
4.44
-0.03
-0.67%
ATEC
1.39
+0.01
+0.72%
CNAT
5.16
-0.08
-1.53%
CRXM
0.327
-0.033
-9.2778%
CYTX
0.548
-0.003
-0.5449%
DXCM
79.36
-0.41
-0.51%
GNMK
8.91
+0.16
+1.83%
HALO
22.1
-0.4
-1.78%
ILMN
220.07
-0.61
-0.28%
INNV
0.12
0.00
0.00%
INO
7.92
-0.22
-2.70%
ISCO
0.043
-0.004
-7.527%
ISIS
56.13
-1.03
-1.80%
LGND
98.6
+1.51
+1.56%
LPTN
0.275
-0.005
-1.6446%
MBVX
2.71
+0.19
+7.54%
MEIP
1.77
+0.07
+4.12%
MNOV
4.02
+0.09
+2.29%
MRTX
31.3
-0.39
-1.23%
MSTX
0.48
-0.01
-2.04%
NBIX
47.31
-0.35
-0.73%
NUVA
47.29
-0.23
-0.48%
ONCS
6.35
-0.25
-3.79%
ONVO
3.74
+0.03
+0.81%
OREX
4.76
-0.17
-3.45%
OTIC
22.09
-0.52
-2.30%
QDEL
23.01
+0.04
+0.17%
RCPT
194.91
-1.36
-0.69%
RGLS
10.2
-0.34
-3.23%
RMD
55.31
+0.01
+0.02%
SCIE
0.016
0.00
0.00%
SPHS
0.823
+0.04
+5.149%
SRNE
16.68
-0.53
-3.08%
TROV
9.53
-0.19
-1.95%
VICL
0.7
+0.015
+2.1752%
ZGNX
12.8
-1.16
-8.31%
ACAD
41.69
+0.02
+0.05%
AEMD
6.9
-0.1
-1.43%
APRI
1.85
+0.17
+10.12%
ARNA
4.44
-0.03
-0.67%
ATEC
1.39
+0.01
+0.72%
CNAT
5.16
-0.08
-1.53%
CRXM
0.327
-0.033
-9.2778%
CYTX
0.548
-0.003
-0.5449%
DXCM
79.36
-0.41
-0.51%
GNMK
8.91
+0.16
+1.83%
HALO
22.1
-0.4
-1.78%
ILMN
220.07
-0.61
-0.28%
INNV
0.12
0.00
0.00%
INO
7.92
-0.22
-2.70%
ISCO
0.043
-0.004
-7.527%
ISIS
56.13
-1.03
-1.80%
LGND
98.6
+1.51
+1.56%
LPTN
0.275
-0.005
-1.6446%
MBVX
2.71
+0.19
+7.54%
MEIP
1.77
+0.07
+4.12%
MNOV
4.02
+0.09
+2.29%
MRTX
31.3
-0.39
-1.23%
MSTX
0.48
-0.01
-2.04%
NBIX
47.31
-0.35
-0.73%
NUVA
47.29
-0.23
-0.48%
ONCS
6.35
-0.25
-3.79%
ONVO
3.74
+0.03
+0.81%
OREX
4.76
-0.17
-3.45%
OTIC
22.09
-0.52
-2.30%
QDEL
23.01
+0.04
+0.17%
RCPT
194.91
-1.36
-0.69%
RGLS
10.2
-0.34
-3.23%
RMD
55.31
+0.01
+0.02%
SCIE
0.016
0.00
0.00%
SPHS
0.823
+0.04
+5.149%
SRNE
16.68
-0.53
-3.08%
TROV
9.53
-0.19
-1.95%
VICL
0.7
+0.015
+2.1752%
ZGNX
12.8
-1.16
-8.31%
Home » Bio: Kevin Lustig

Bio: Kevin Lustig

Recently named one of five national finalists for “Entrepreneur of the Year” by Entrepreneur magazine, Kevin is a cell biologist with 30 years of research experience in academia and pharma. He is founder and CEO of Assay Depot, a software company that is transforming how medical research is done.  In 2013, he founded Bio, Tech and Beyond, a non-profit community laboratory dedicated to life science innovation.  In 2001, Kevin founded Kalypsys, a biopharmaceutical company that raised over $170 million in venture funding and put five drug candidates into clinical trials. Prior to Kalypsys, he directed lead discovery at Tularik, a biopharmaceutical company purchased by Amgen for $2.5 billion. He carried out postdoctoral work in Cell Biology at Harvard Medical School after receiving a PhD degree from the University of California, San Francisco. Kevin has a M.S. degree from the University of Missouri, Columbia and an A.B. degree, magna cum laude, from Cornell University.  His research discoveries have been published in Science, Nature and other leading scientific journals and he has eight technology patents.